Overview
- Novartis reported a 28.4% relative reduction in recurrence with ribociclib plus endocrine therapy versus endocrine therapy alone in the five-year analysis.
- Five-year invasive disease-free survival was 85.5% with ribociclib plus endocrine therapy compared with 81.0% with endocrine therapy alone, a 4.5 percentage-point absolute gain.
- Overall survival showed an improved hazard ratio of 0.800, with five-year rates of 94.1% versus 92.5%, indicating an encouraging but still developing signal.
- Benefits persisted roughly two years after completion of the three-year ribociclib course, with no new safety signals reported at approximately five years of follow-up.
- Investigators also observed significant improvements in distant endpoints (DDFS HR 0.709; DRFS HR 0.699), and the trial will keep collecting data to solidify long-term outcomes.